Literature DB >> 21839364

Minimal change disease: a CD80 podocytopathy?

Takuji Ishimoto1, Michiko Shimada, Carlos E Araya, Janna Huskey, Eduardo H Garin, Richard J Johnson.   

Abstract

Minimal change disease is the most common nephrotic syndrome in children. Although the etiology of minimal change disease remains to be elucidated, it has been postulated that it is the result of a circulating T-cell factor that causes podocyte cytoskeleton disorganization leading to increased glomerular capillary permeability and/or changes in glomerular basement membrane heparan sulfate glycosaminoglycans resulting in proteinuria. Minimal change disease has been associated with allergies and Hodgkin disease. Consistent with these associations, a role for interleukin-13 with minimal change disease has been proposed. Furthermore, studies evaluating podocytes also have evolved. Recently, increased expression of CD80 (also termed B7-1) on podocytes was identified as a mechanism for proteinuria. CD80 is inhibited by binding to CTLA-4, which is expressed on regulatory T cells. Recently, we showed that urinary CD80 is increased in minimal change disease patients and limited studies have suggested that it is not commonly present in the urine of patients with other glomerular diseases. Interleukin-13 or microbial products via Toll-like receptors could be factors that induce CD80 expression on podocytes. CTLA-4 appears to regulate CD80 expression in podocytes, and to be altered in minimal change disease patients. These findings lead us to suggest that proteinuria in minimal change disease is caused by persistent CD80 expression in podocytes, possibly initiated by stimulation of these cells by antigens or cytokines.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21839364     DOI: 10.1016/j.semnephrol.2011.06.002

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  16 in total

1.  Urine and serum ghrelin, sCD80 and sCTLA-4 levels in doxorubicin-induced experimental nephrotic syndrome.

Authors:  Duygu Ozkorucu; Nuran Cetin; Nadide Melike Sav; Bilal Yildiz
Journal:  Int Urol Nephrol       Date:  2016-02-27       Impact factor: 2.370

2.  American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis.

Authors:  Fernando C Fervenza; Mark A Perazella; Michael J Choi
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

3.  Relapse of minimal change disease following infection with the 2009 pandemic influenza (H1N1) virus.

Authors:  Seo Rin Kim; Soo Bong Lee; Il Young Kim; Dong Won Lee; Harin Rhee; Eun Young Seong; Sang Heon Song; Ihm Soo Kwak
Journal:  Clin Exp Nephrol       Date:  2011-11-25       Impact factor: 2.801

4.  Costimulatory blockade: A novel approach to the treatment of glomerular disease?

Authors:  Pasquale Esposito; Teresa Rampino; Antonio Dal Canton
Journal:  World J Methodol       Date:  2015-06-26

5.  LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: changes in TLR profile.

Authors:  Tarak Srivastava; Mukut Sharma; Kok-Hooi Yew; Ram Sharma; R Scott Duncan; Moin A Saleem; Ellen T McCarthy; Alexander Kats; Patricia A Cudmore; Uri S Alon; Christopher J Harrison
Journal:  J Cell Commun Signal       Date:  2012-11-17       Impact factor: 5.782

6.  Suppression by Δ(9)-tetrahydrocannabinol of the primary immunoglobulin M response by human peripheral blood B cells is associated with impaired STAT3 activation.

Authors:  Thitirat Ngaotepprutaram; Barbara L F Kaplan; Stephen Carney; Robert Crawford; Norbert E Kaminski
Journal:  Toxicology       Date:  2013-05-29       Impact factor: 4.221

7.  Minimal change nephrotic syndrome associated with non-Hodgkin lymphoid disorders: a retrospective study of 18 cases.

Authors:  Tomek Kofman; Shao-Yu Zhang; Christiane Copie-Bergman; Anissa Moktefi; Quentin Raimbourg; Hélène Francois; Alexandre Karras; Emmanuelle Plaisier; Bernard Painchart; Guillaume Favre; Dominique Bertrand; Emmanuel Gyan; Marc Souid; Damien Roos-Weil; Dominique Desvaux; Philippe Grimbert; Corinne Haioun; Philippe Lang; Djillali Sahali; Vincent Audard
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

Review 8.  Remaining Physiological Barriers in Porcine Kidney Xenotransplantation: Potential Pathways behind Proteinuria as well as Factors Related to Growth Discrepancies following Pig-to-Kidney Xenotransplantation.

Authors:  Jigesh A Shah; Miguel A Lanaspa; Tatsu Tanabe; Hironosuke Watanabe; Richard J Johnson; Kazuhiko Yamada
Journal:  J Immunol Res       Date:  2018-03-04       Impact factor: 4.818

9.  Effects of melanocortin 1 receptor agonists in experimental nephropathies.

Authors:  Annika Lindskog Jonsson; Anna Granqvist; Johannes Elvin; Martin E Johansson; Börje Haraldsson; Jenny Nyström
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

10.  TLR-mediated albuminuria needs TNFα-mediated cooperativity between TLRs present in hematopoietic tissues and CD80 present on non-hematopoietic tissues in mice.

Authors:  Nidhi Jain; Bhavya Khullar; Neelam Oswal; Balaji Banoth; Prashant Joshi; Balachandran Ravindran; Subrat Panda; Soumen Basak; Anna George; Satyajit Rath; Vineeta Bal; Shailaja Sopory
Journal:  Dis Model Mech       Date:  2016-04-28       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.